loader
Please Wait
Applying Filters...

Annual Sales of Focalin reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

Menu
$ API Ref.Price (USD/KG) : 5,085Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 1Neoral/Sandimmun(e)

PharmaCompass

01

Brand Name : Neoral/Sandimmun(e)

Dexmethylphenidate

arrow
Pharmaconex 2024
Not Confirmed

Brand Name : Neoral/Sandimmun(e)

arrow
Pharmaconex 2024
Not Confirmed

Dexmethylphenidate

Main Therapeutic Indication : CNS & Anesthesia

Currency : USD

2020 Revenue in Millions : 393

2019 Revenue in Millions : 419

Growth (%) : -6

blank

02

Brand Name : Neoral/Sandimmun(e)

Dexmethylphenidate

arrow
Pharmaconex 2024
Not Confirmed

Brand Name : Neoral/Sandimmun(e)

arrow
Pharmaconex 2024
Not Confirmed

Dexmethylphenidate

Main Therapeutic Indication : Neurology

Currency : USD

2021 Revenue in Millions : 368

2020 Revenue in Millions : 393

Growth (%) : -6

blank

03

Brand Name : Ritalin/Focalin

Dexmethylphenidate

arrow
Pharmaconex 2024
Not Confirmed

Brand Name : Ritalin/Focalin

arrow
Pharmaconex 2024
Not Confirmed

Dexmethylphenidate

Main Therapeutic Indication : Neurological/Mental Disorders

Currency : USD

2016 Revenue in Millions : 282

2015 Revenue in Millions : 365

Growth (%) : -23

blank

04

Brand Name : Ritalin/Focalin

Dexmethylphenidate

arrow
Pharmaconex 2024
Not Confirmed

Brand Name : Ritalin/Focalin

arrow
Pharmaconex 2024
Not Confirmed

Dexmethylphenidate

Main Therapeutic Indication : Neurological/Mental Disorders

Currency : USD

2017 Revenue in Millions : 236

2016 Revenue in Millions : 282

Growth (%) : -16

blank

05

Brand Name : Neoral/Sandimmun(E)

Dexmethylphenidate

arrow
Pharmaconex 2024
Not Confirmed

Brand Name : Neoral/Sandimmun(E)

arrow
Pharmaconex 2024
Not Confirmed

Dexmethylphenidate

Main Therapeutic Indication : Neurological/Mental Disorders

Currency : USD

2018 Revenue in Millions : 463

2017 Revenue in Millions : 488

Growth (%) : -5%

blank

06

Brand Name : Neoral/Sandimmun(e)

Dexmethylphenidate

arrow
Pharmaconex 2024
Not Confirmed

Brand Name : Neoral/Sandimmun(e)

arrow
Pharmaconex 2024
Not Confirmed

Dexmethylphenidate

Main Therapeutic Indication : CNS & Anesthesia

Currency : USD

2019 Revenue in Millions : 419

2018 Revenue in Millions : 463

Growth (%) : -10

blank